1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Mental Health Analysis & Statistics in Japan, July 2020

Mental Health Analysis & Statistics in Japan, July 2020

1-30 of about 100 reports

Diabetic Peripheral Neuropathy (DPN) - Epidemiology Forecast-2030

  • $ 3750
  • Jul 2020
  • 80 pages

‘Diabetic Peripheral Neuropathy (DPN) - Epidemiology Forecast-2030’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology trends of Diabetic Peripheral Neuropathy ...

  • Mental Health
  • Neurological Disorder
  • Pathology
  • Japan
  • United States

Alzheimer’s Disease: Global Drug Forecast and Market Analysis to 2028

  • $ 10995
  • May 2020
  • 218 pages

Alzheimer’s Disease: Global Drug Forecast and Market Analysis to 2028 Summary Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, ...

  • Mental Health
  • Japan
  • Allergan plc
  • Biogen Idec Inc.
  • Eisai Co., Ltd.

Alzheimer’s Disease: Epidemiology Forecast to 2028

  • $ 3995
  • May 2020
  • 47 pages

Alzheimer’s Disease: Epidemiology Forecast to 2028 Summary Alzheimer’s Disease (AD) is a subtype of dementia and is an irreversible, neurodegenerative brain disease of the elderly.AD is characterized ...

  • Dementia
  • Mental Health
  • Pathology
  • Japan
  • Forecast

Pompe Disease - Epidemiology Forecast to 2030

  • $ 3750
  • May 2020
  • 100 pages

‘Pompe Disease (PD) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Pompe Disease in the United States, EU5 (Germany, ...

  • Mental Health
  • Neurological Disorder
  • Pathology
  • Japan
  • United Kingdom

Frontotemporal Dementia (FTD)- Epidemiology Forecast to 2030

  • $ 3750
  • May 2020
  • 100 pages

‘Frontotemporal Dementia (FTD) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Frontotemporal Dementia in the United ...

  • Mental Health
  • Neurological Disorder
  • Pathology
  • Japan
  • United States

Postpartum Depression - Epidemiology Forecast to 2030

  • $ 3750
  • April 2020
  • 100 pages

‘Postpartum Depression (PPD) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Postpartum Depression (PPD) epidemiology in the United ...

  • Depression
  • Mental Health
  • Germany
  • Japan
  • Forecast

Duchenne Muscular Dystrophy - Epidemiology Forecast to 2030

  • $ 3750
  • April 2020
  • 100 pages

‘Duchenne Muscular Dystrophy (DMD) - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Duchenne Muscular Dystrophy (DMD) epidemiology ...

  • Mental Health
  • Neurological Disorder
  • Pathology
  • Japan
  • United States

Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030

  • $ 3750
  • April 2020
  • 83 pages

Overview ‘Adrenoleukodystrophy (ALD) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Adrenoleukodystrophy epidemiology in the 7MM, ...

  • Mental Health
  • Neurological Disorder
  • Japan
  • United Kingdom
  • United States

5-Hydroxytryptamine Receptor 7 - Pipeline Review, H1 2020

  • $ 3500
  • March 2020
  • 74 pages

5-Hydroxytryptamine Receptor 7 - Pipeline Review, H1 2020 Summary 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and ...

  • Depression
  • Mental Health
  • Pharmaceutical
  • Japan
  • Product Initiative

Japan Neurology Devices Market Outlook to 2025 - Hydrocephalus shunts, Interventional Neuroradiology, Minimally Invasive Neurosurgery and Others.

  • $ 5995
  • January 2020
  • 191 pages

Japan Neurology Devices Market Outlook to 2025 - Hydrocephalus shunts, Interventional Neuroradiology, Minimally Invasive Neurosurgery and Others. Summary new report, Japan Neurology Devices Market Outlook ...

  • Catheter
  • Hospital
  • Mental Health
  • Japan
  • Teijin Limited

Acyl CoA Desaturase - Pipeline Review, H1 2020

  • $ 3500
  • January 2020
  • 51 pages

Acyl CoA Desaturase - Pipeline Review, H1 2020 Summary According to the recently published report ’Acyl CoA Desaturase - Pipeline Review, H1 2020’; Acyl CoA Desaturase (Fatty Acid Desaturase or Delta ...

  • Mental Health
  • Therapy
  • Japan
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.

Beta Secretase 1 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020
  • 34 pages

Beta Secretase 1 - Pipeline Review, H1 2020 Summary According to the recently published report ’Beta Secretase 1 - Pipeline Review, H1 2020’; Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid ...

  • Dementia
  • Mental Health
  • Therapy
  • Japan
  • Product Initiative

Alpha 2C Adrenergic Receptor - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 49 pages

Alpha 2C Adrenergic Receptor - Pipeline Review, H2 2019 Summary Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Alpha-2C adrenergic recepto ...

  • Mental Health
  • Europe
  • Japan
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.

Acyl CoA Desaturase - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 51 pages

Acyl CoA Desaturase - Pipeline Review, H2 2019 Summary Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) pipeline Target constitutes close ...

  • Mental Health
  • Therapy
  • Japan
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.

Hepatocyte Growth Factor - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 76 pages

Hepatocyte Growth Factor - Pipeline Review, H2 2019 Summary Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 13 molecules. The latest report Hepatocyte ...

  • Cancer
  • Mental Health
  • Pharmaceutical
  • Japan
  • AnGes MG, Inc.

Multiple Sclerosis: Epidemiology Forecast to 2028

  • $ 3995
  • November 2019
  • 38 pages

Multiple Sclerosis: Epidemiology Forecast to 2028 Summary Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed ...

  • Health Services
  • Mental Health
  • Italy
  • Japan
  • Forecast

Embolotherapy Market

  • $ 4900
  • September 2019
  • 336 pages

Embolotherapy Market Research Report: By Product (Embolic Agents, Support Devices), Procedure (Transcatheter Arterial Embolization, Transarterial Radioembolization/Selective Internal Radiation Therapy, ...

  • Mental Health
  • Pathology
  • France
  • Japan
  • Demand

Post-Traumatic Stress Disorder: Epidemiology Forecast to 2028

  • $ 3995
  • June 2019
  • 26 pages

Post-Traumatic Stress Disorder: Epidemiology Forecast to 2028 Summary Post-Traumatic Stress Disorder (PTSD) is a psychiatric disorder that can occur in people who have experienced or witnessed a traumatic ...

  • Anxiety Disorder
  • Mental Health
  • Pathology
  • Japan
  • Forecast

Seroquel/Seroquel XR, Pharma Intelligence

  • $ 10000
  • March 2019
  • 48 pages

The Seroquel franchise contains quetiapine, which acts as an antagonist at multiple neurotransmitter receptors in the brain, such as serotonin 5-HT1A and 5-HT2, dopamine D1 and D2, histamine H1, and adrenergic ...

  • Bipolar Disorder
  • Mental Health
  • Pathology
  • Psychotic Disorder
  • Japan

Rexulti

  • $ 10000
  • March 2019
  • 33 pages

Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; ...

  • Depression
  • Mental Health
  • Pathology
  • Psychotic Disorder
  • Japan

Cymbalta

  • $ 10000
  • March 2019
  • 25 pages

Eli Lilly’s Cymbalta (duloxetine), a serotonin-norepinephrine reuptake inhibitor, was initially approved in the US in August 2004 for the treatment of major depressive disorder. The company has since ...

  • Chronic Pain
  • Depression
  • Mental Health
  • Japan
  • United States

Abilify/Abilify Maintena, Pharma Intelligence

  • $ 10000
  • March 2019
  • 62 pages

Abilify (aripiprazole; Otsuka/Lundbeck) is an atypical antipsychotic that contains aripiprazole, a partial agonist of dopamine receptor D2 and serotonin receptor 5-HT1A, and antagonist of the 5-HT2A ...

  • Mental Health
  • Pathology
  • Psychotic Disorder
  • Japan
  • United States

Latuda

  • $ 10000
  • March 2019
  • 39 pages

Latuda (lurasidone; Sumitomo Dainippon/Angelini) contains the atypical antipsychotic lurasidone, which acts as an antagonist of dopamine receptors D2, and serotonin receptors 5-HT2A. By inhibiting the ...

  • Mental Health
  • Pathology
  • Psychotic Disorder
  • Germany
  • Japan

Alzheimer’s Disease Market and Forecast Analysis 2034

  • $ 22000
  • February 2019
  • 300 pages

Disease Overview Alzheimer’s disease is an irreversible, progressive, neurodegenerative, and fatal disease that slowly affects memory, cognition, and function. Alzheimer’s disease is the most common ...

  • Dementia
  • Mental Health
  • European Union
  • Japan
  • United States

Kyorin Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • December 2018
  • 48 pages

Summary Kyorin Pharmaceutical Co Ltd (Kyorin), a subsidiary of Kyorin Holdings Inc, is a pharmaceutical company that manufactures and markets prescription medicines.The company offers ethical drugs including ...

  • Healthcare
  • Mental Health
  • Pharmaceutical
  • Japan
  • Kyorin Pharmaceutical Co., Ltd.

Japan Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others

  • $ 5995
  • November 2018
  • 163 pages

Japan Neurology Devices Market Outlook to 2025 - Hydrocephalus Shunts, Interventional Neuroradiology Devices, Neurosurgical Products and Others Summary GlobalData’s new report, Japan Neurology Devices ...

  • Hospital
  • Mental Health
  • Neurological Disorder
  • Japan
  • Medtronic, Inc.

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

  • $ 3500
  • October 2018
  • 62 pages

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018 Su ...

  • Mental Health
  • Psychotic Disorder
  • Therapy
  • Japan
  • Protalix BioTherapeutics, Inc.

Multiple Sclerosis Forecast and Market Analysis to 2025, Pharma Intelligence

  • $ 22000
  • July 2018
  • 765 pages

DISEASE OVERVIEW Multiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal demyelination leading to physical and cognitive disability. Although the etiology of MS is uncertain, ...

  • Mental Health
  • Neurological Disorder
  • European Union
  • Japan
  • United States

Epilepsy Forecast and Market Analysis to 2035

  • $ 22000
  • July 2018
  • 345 pages

DISEASE OVERVIEW Epilepsy is characterized by recurrent, unprovoked seizures. A seizure occurs when the normal pattern of neuronal activity is disturbed, defined by the National Institute of Neurological ...

  • Mental Health
  • Neurological Disorder
  • Japan
  • United States
  • Demand

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027

  • $ 10995
  • July 2018
  • 95 pages

Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027 Summary Amyotrophic Lateral Sclerosis (ALS) drug sales in 2017 were approximately $187M across the seven major markets - the US, ...

  • Mental Health
  • Therapy
  • Japan
  • Forecast
  • Ionis Pharmaceuticals, Inc.

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on